JP2021518132A5 - - Google Patents

Info

Publication number
JP2021518132A5
JP2021518132A5 JP2020550641A JP2020550641A JP2021518132A5 JP 2021518132 A5 JP2021518132 A5 JP 2021518132A5 JP 2020550641 A JP2020550641 A JP 2020550641A JP 2020550641 A JP2020550641 A JP 2020550641A JP 2021518132 A5 JP2021518132 A5 JP 2021518132A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
glp
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518132A (ja
JP7313372B2 (ja
Filing date
Publication date
Priority claimed from CN201810231468.XA external-priority patent/CN110305211A/zh
Application filed filed Critical
Publication of JP2021518132A publication Critical patent/JP2021518132A/ja
Publication of JP2021518132A5 publication Critical patent/JP2021518132A5/ja
Application granted granted Critical
Publication of JP7313372B2 publication Critical patent/JP7313372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550641A 2018-03-20 2019-03-19 Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 Active JP7313372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810231468.XA CN110305211A (zh) 2018-03-20 2018-03-20 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN201810231468.X 2018-03-20
PCT/CN2019/078671 WO2019179424A1 (zh) 2018-03-20 2019-03-19 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用

Publications (3)

Publication Number Publication Date
JP2021518132A JP2021518132A (ja) 2021-08-02
JP2021518132A5 true JP2021518132A5 (cg-RX-API-DMAC7.html) 2022-04-18
JP7313372B2 JP7313372B2 (ja) 2023-07-24

Family

ID=67986692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550641A Active JP7313372B2 (ja) 2018-03-20 2019-03-19 Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途

Country Status (10)

Country Link
US (1) US11780916B2 (cg-RX-API-DMAC7.html)
EP (1) EP3808771A4 (cg-RX-API-DMAC7.html)
JP (1) JP7313372B2 (cg-RX-API-DMAC7.html)
KR (1) KR102967396B1 (cg-RX-API-DMAC7.html)
CN (3) CN117126279A (cg-RX-API-DMAC7.html)
AU (1) AU2019236822B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019052A2 (cg-RX-API-DMAC7.html)
CA (1) CA3094286A1 (cg-RX-API-DMAC7.html)
TW (1) TWI832847B (cg-RX-API-DMAC7.html)
WO (1) WO2019179424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN115141276A (zh) * 2021-03-31 2022-10-04 鸿运华宁(杭州)生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
EP4352104A4 (en) * 2021-06-09 2025-06-04 Swiftnovo Therapeutics Inc. Therapeutics and methods for treating or ameliorating metabolic disorders
AU2023337288A1 (en) * 2022-09-08 2025-03-13 Gmax Biopharm Llc Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
CN117986361A (zh) * 2022-11-02 2024-05-07 苏州康宁杰瑞生物科技有限公司 一种gipr结合蛋白及其应用
TW202611076A (zh) * 2024-05-15 2026-03-16 大陸商信立泰(成都)生物技術有限公司 一種抗gipr抗體或其抗原結合片段及用途
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026093993A1 (en) * 2024-11-01 2026-05-07 Janssen Biotech, Inc. Methods and systems for enhanced multispecific metabolic and cellular targeting

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
WO2016167306A1 (ja) 2015-04-16 2016-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ヒトNotch4抗体
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法

Similar Documents

Publication Publication Date Title
JP2022549172A5 (cg-RX-API-DMAC7.html)
US20240076370A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
JP2024150751A5 (cg-RX-API-DMAC7.html)
US10913796B2 (en) Antibodies targeting Fc receptor-like 5 and methods of use
JP2020180158A5 (cg-RX-API-DMAC7.html)
JP2023051986A (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
JP2022031635A5 (cg-RX-API-DMAC7.html)
JP2022512234A5 (cg-RX-API-DMAC7.html)
JP2020524661A5 (cg-RX-API-DMAC7.html)
RU2016108703A (ru) Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2019520797A5 (cg-RX-API-DMAC7.html)
JP2019504032A5 (cg-RX-API-DMAC7.html)
US11851460B2 (en) PD1 binding agents
JP2018522888A5 (cg-RX-API-DMAC7.html)
US20160168247A1 (en) Humanized or chimeric cd3 antibodies
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2022553922A5 (cg-RX-API-DMAC7.html)
JP2023516195A (ja) C19 c38二特異性抗体
JP2022545741A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
CN114786720B (zh) TriAx抗体的组合物及其制备和使用方法
JP2021518748A5 (cg-RX-API-DMAC7.html)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2021526833A5 (cg-RX-API-DMAC7.html)